Disclosures: Francisco Caballero-Camino: Nothing to Disclose, Irune Lasa: Nothing to Disclose, Ainhoa Lapitz: Nothing to Disclose, Xia Wu: CymaBay Therapeutics: Employee, Pedro Rodrigues: Nothing to Disclose, Noelia Pastor-Toyos: Nothing to Disclose, Laura Izquierdo-Sanchez: Nothing to Disclose, Jiangao Song: Nothing to Disclose, Edward Cable: CymaBay Therapetics: Employee, Jeffrey Johnson: CymaBay Therapeutics: Consultant, Yun-Jung Choi: Nothing to Disclose, Charles McWherter: Nothing to Disclose, Jesus Banales: Nothing to Disclose 2077 REGULATION OF HEPATIC MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3/ATP-BINDING CASSETTE SUBFAMILY C MEMBER 3 (MRP3/ABCC3) BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR): A NOVEL MECHANISM TO REDUCE BILE ACID INJURY DURING CHOLESTASIS Colleen Hayes 1 Gina Gallucci 1 James Boyer 2 David Assis 2 Nisanne Ghonem 1 , 1 University of Rhode Island, 2 Yale School of Medicine, Liver Center Background: Cholestatic liver diseases are characterized by the accumulation of toxic bile acids
While rare, its possible to experience pancreatitis (inflammation of the pancreas), kidney problems (like kidney stones), acute gallbladder disease, and an increased risk of thyroid cancer
"But the effects are modest and the evidence is not yet sufficient to support using genetic information to guide treatment decisions in routine clinical practice."
Diabetes 13, 3 (2023)
They can help you find solutions, whether that's getting a new prescription, finding patient assistance programs, or exploring alternative medications
As of July 1, there are 3,848 pending actions in the MDL
